Effect of same cream for different duration.
Not Applicable
- Conditions
- Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue
- Registration Number
- CTRI/2019/03/018222
- Lead Sponsor
- Department of Dermatology and Venereology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Topical adapalene to be applied all over face as advised by split face technique
Exclusion Criteria
1. Pregnant women
2. Breastfeeding women
3. Not giving informed consent
4. Known intolerance to adapalene
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To reduce lesions of acne within 12 weeksTimepoint: To reduce lesions of acne within 12 weeks
- Secondary Outcome Measures
Name Time Method To reduce overall skin irritation and post inflammatory hyperpigmentation of lesions of acneTimepoint: 4 weeks, 8 weeks and 12 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does topical adapalene application duration affect retinoic acid receptor (RAR) activation in acne vulgaris pathogenesis?
What comparative efficacy data exists for adapalene vs. tretinoin or benzoyl peroxide in acne vulgaris treatment regimens?
Which biomarkers predict response to topical adapalene dosing frequency in CTRI/2019/03/018222 acne vulgaris trial?
What adverse event profiles emerge from prolonged topical adapalene use in inflammatory acne vulgaris patients?
What synergistic effects are observed when combining adapalene with clindamycin or other retinoids for acne vulgaris management?